Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Oral administration of iron-saturated bovine lactoferrin–loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism

Authors Mahidhara G, Kanwar RK, Roy K, Kanwar JR

Received 15 October 2014

Accepted for publication 28 November 2014

Published 22 June 2015 Volume 2015:10(1) Pages 4081—4098

DOI https://doi.org/10.2147/IJN.S75877

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Carlos Rinaldi

Ganesh Mahidhara, Rupinder K Kanwar, Kislay Roy, Jagat R Kanwar

Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research, School of Medicine, Molecular and Medical Research Strategic Research Centre, Faculty of Health, Deakin University, Waurn Ponds, VIC, Australia

Abstract: We determined the anticancer efficacy and internalization mechanism of our polymeric–ceramic nanoparticle system (calcium phosphate nanocores, enclosed in biodegradable polymers chitosan and alginate nanocapsules/nanocarriers [ACSC NCs]) loaded with iron-saturated bovine lactoferrin (Fe-bLf) in a breast cancer xenograft model. ACSC-Fe-bLf NCs with an overall size of 322±27.2 nm were synthesized. In vitro internalization and anticancer efficacy were evaluated in the MDA-MB-231 cells using multicellular tumor spheroids, CyQUANT and MTT assays. These NCs were orally delivered in a breast cancer xenograft mice model, and their internalization, cytotoxicity, biodistribution, and anticancer efficacy were evaluated. Chitosan-coated calcium phosphate Fe-bLf NCs effectively (59%, P≤0.005) internalized in a 1-hour period using clathrin-mediated endocytosis (P≤0.05) and energy-mediated pathways (P≤0.05) for internalization; 3.3 mg/mL of ACSC-Fe-bLf NCs completely disintegrated (~130-fold reduction, P≤0.0005) the tumor spheroids in 72 hours and 96 hours. The IC50 values determined for ACSC-Fe-bLf NCs were 1.69 mg/mL at 10 hours and 1.62 mg/mL after 20 hours. We found that Fe-bLf-NCs effectively (P≤0.05) decreased the tumor size (4.8-fold) compared to the void NCs diet and prevented tumor recurrence when compared to intraperitoneal injection of Taxol and Doxorubicin. Receptor gene expression and micro-RNA analysis confirmed upregulation of low-density lipoprotein receptor and transferrin receptor (liver, intestine, and brain). Several micro-RNAs responsible for iron metabolism upregulated with NCs were identified. Taken together, orally delivered Fe-bLf NCs offer enhanced antitumor activity in breast cancer by internalizing via low-density lipoprotein receptor and transferrin receptor and regulating the micro-RNA expression. These NCs also restored the body iron and calcium levels and increased the hematologic counts.

Keywords: oral delivery, Fe-bLf, miRNA, xenograft, breast cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Cissus quadrangularis inhibits IL-1β induced inflammatory responses on chondrocytes and alleviates bone deterioration in osteotomized rats via p38 MAPK signaling [Corrigendum]

Kanwar JR, Samarasinghe RM, Kumar K, Arya R, Sanjeev S, Zhou SF, Sasidharan S, Kanwar RK

Drug Design, Development and Therapy 2017, 11:2683-2684

Published Date: 12 September 2017

Theranostic multimodular potential of zinc-doped ferrite-saturated metal-binding protein-loaded novel nanocapsules in cancers

Kamalapuram SK, Kanwar RK, Roy K, Chaudhary R, Sehgal R, Kanwar JR

International Journal of Nanomedicine 2016, 11:1349-1366

Published Date: 1 April 2016

Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells

Roy K, Patel YS, Kanwar RK, Rajkhowa R, Wang X, Kanwar JR

International Journal of Nanomedicine 2016, 11:25-44

Published Date: 21 December 2015

Neurobehavioral burden of multiple sclerosis with nanotheranostics

Sriramoju B, Kanwar RK, Kanwar JR

Neuropsychiatric Disease and Treatment 2015, 11:2675-2689

Published Date: 15 October 2015

Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondii

Anand N, Sehgal R, Kanwar RK, Dubey ML, Vasishta RK, Kanwar JR

International Journal of Nanomedicine 2015, 10:6355-6369

Published Date: 8 October 2015

Molecular targets in arthritis and recent trends in nanotherapy

Roy K, Kanwar RK, Kanwar JR

International Journal of Nanomedicine 2015, 10:5407-5420

Published Date: 26 August 2015

Effect of lactoferrin protein on red blood cells and macrophages: mechanism of parasite–host interaction

Anand N, Kanwar RK, Dubey ML, Vahishta RK, Sehgal R, Verma AK, Kanwar JR

Drug Design, Development and Therapy 2015, 9:3821-3835

Published Date: 27 July 2015

Cissus quadrangularis inhibits IL-1β induced inflammatory responses on chondrocytes and alleviates bone deterioration in osteotomized rats via p38 MAPK signaling

Kanwar JR, Samarasinghe RM, Kumar K, Arya R, Sharma S, Zhou SF, Sasidharan S, Kanwar RK

Drug Design, Development and Therapy 2015, 9:2927-2940

Published Date: 5 June 2015

Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model

Roy K, Kanwar RK, Krishnakumar S, Cheung CH, Kanwar JR

International Journal of Nanomedicine 2015, 10:1019-1043

Published Date: 2 February 2015

Nanoformulated cell-penetrating survivin mutant and its dual actions

Sriramoju B, Kanwar RK, Kanwar JR

International Journal of Nanomedicine 2014, 9:3279-3298

Published Date: 10 July 2014

Neurological disorders and therapeutics targeted to surmount the blood–brain barrier

Kanwar JR, Sriramoju B, Kanwar RK

International Journal of Nanomedicine 2012, 7:3259-3278

Published Date: 9 July 2012

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

A new recombinant factor VIII: from genetics to clinical use

Kannicht C, Kohla G, Tiemeyer M, Walter O, Sandberg H

Drug Design, Development and Therapy 2015, 9:3817-3819

Published Date: 23 July 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010